[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Moogene Medi Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100630642",false,"NCT07490327","Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia","A Randomized, Open-label, Single and Multiple-dose, Parallel-design Phase 1\u002F2a Clinical Trial to Evaluate the Pharmacokinetics\u002FPharmacodynamics and Safety of AD-303A and Oral Administration of AD-3031 in Male Androgenetic Alopecia Patients","Inclusion Criteria:\n\n* Male participants aged 19 to 55 years.\n* Clinical diagnosis of androgenetic alopecia.\n* Healthy as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests.\n* Willing and able to comply with all study procedures and visit schedules.\n\nExclusion Criteria:\n\n* History or presence of dermatologic conditions affecting the scalp other than androgenetic alopecia.\n* Prior hair transplantation or scalp surgery that may affect evaluation of hair growth.\n* Use of medications known to affect hair growth (e.g., finasteride, dutasteride, minoxidil) within 6 months prior to screening.",true,"MALE","19 Years","55 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a randomized, open-label phase 1\u002F2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.",[28],"Androgenetic Alopecia",[30,28,31,32,33,34,35],"AD-303A \u002F AD-3031","Dutasteride","Topical","5-Alpha Reductase Inhibitor","Pharmacokinetics","Safety","NOT_YET_RECRUITING","2026-03-19",{"date":39,"type":40},"2026-03-24","ACTUAL",{"date":42,"type":21},"2026-04",{"date":44,"type":21},"2026-12",{"name":46,"class":47},"Moogene Medi Co., Ltd","INDUSTRY",""]